


	Apixaban	Dabigatran	Edoxaban	Rivaroxaban	VKA
Apixaban	Apixaban	2.09 (1.49, 2.89)	1.61 (0.87, 2.83)	1.29 (0.94, 1.78)	1.87 (1.37, 2.43)
Dabigatran	0.48 (0.35, 0.67)	Dabigatran	0.77 (0.42, 1.35)	0.62 (0.45, 0.85)	0.89 (0.66, 1.17)
Edoxaban	0.62 (0.35, 1.15)	1.3 (0.74, 2.38)	Edoxaban	0.8 (0.46, 1.47)	1.17 (0.7, 1.95)
Rivaroxaban	0.78 (0.56, 1.07)	1.62 (1.17, 2.21)	1.24 (0.68, 2.17)	Rivaroxaban	1.45 (1.08, 1.85)
VKA	0.53 (0.41, 0.73)	1.12 (0.86, 1.52)	0.86 (0.51, 1.43)	0.69 (0.54, 0.93)	VKA



	Rank 1	Rank 2	Rank 3	Rank 4	Rank 5
Apixaban	0.90876	0.07965	0.01064	0.00084	0.000
Dabigatran	0.00013	0.00258	0.06549	0.19079	0.741
Edoxaban	0.04972	0.15200	0.53630	0.13184	0.130
Rivaroxaban	0.04126	0.76194	0.18680	0.00854	0.001
VKA	0.00013	0.00384	0.20078	0.66800	0.127

comparison	p.value	CrI
d.Apixaban.Dabigatran	0.4813	NA
-> direct	NA	0.82 (0.43, 1.1)
-> indirect	NA	0.54 (-0.30, 1.4)
-> network	NA	0.74 (0.41, 1.1)
d.Apixaban.Rivaroxaban	0.4788	NA
-> direct	NA	0.31 (-0.15, 0.74)
-> indirect	NA	0.028 (-0.79, 0.92)
-> network	NA	0.25 (-0.061, 0.57)
d.Dabigatran.Rivaroxaban	0.9748	NA
-> direct	NA	-0.49 (-0.96, -0.0030)
-> indirect	NA	-0.50 (-1.4, 0.50)
-> network	NA	-0.48 (-0.79, -0.17)

Rank	Intervention
1	Apixaban
2	Rivaroxaban
3	Edoxaban
4	VKA
5	Dabigatran

Supplementary Appendix 10. Sensitivity analysis excluding Lau et al. [19] and Lau et al. [23]: (A) network plot, (B) Bayesian comparison of all treatment pairs, (C) funnel plot, (D) ranking probability table, (E) node-split model for assessment of inconsistency, (F) median rank chart. VKA, vitamin K antagonists; CrI, credible interval.